PMID- 29888721
OWN - NLM
STAT- MEDLINE
DCOM- 20180831
LR  - 20220317
IS  - 1119-3077 (Print)
VI  - 21
IP  - 6
DP  - 2018 Jun
TI  - A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, 
      Southern Iraq.
PG  - 735-742
LID - 10.4103/njcp.njcp_162_17 [doi]
AB  - BACKGROUND: Patients with sickle cell disease (SCD) may require repeated 
      transfusions, which inevitably lead to iron overload (IOL). AIMS: : This study 
      aims to assess the effectiveness and safety of oral deferasirox (DFX) in patients 
      with SCD and transfusional IOL. PATIENTS AND METHODS: A descriptive study has 
      been performed on patients with SCD who have completed at least 3 years on DFX. 
      Height and weight were checked every 3-6 months. The efficacy was assessed based 
      on serum ferritin (SF) levels. The safety was assessed based on adverse events 
      (AEs), alanine aminotransferase (ALT), and serum creatinine (S. Cr) levels. 
      RESULTS: : A total of 102 patients (61 males and 41 females) were recruited. 
      Their mean daily iron intake was 0.13 +/- 0.06 mg/kg. SF levels declined 
      significantly from 2434.1 +/- 132.9 ng/ml at the start of the study to 1655.8 +/- 
      154.2 ng/ml at the end of the study (P < 0.05), with significant decreases 
      observed after increasing the DFX dose to >/= 30 mg/kg/day. ALT (12.8 +/- 9.9 vs. 
      12.1 +/- 7.1 U/L) and S. Cr (72.4 +/- 9.2 vs. 74.1 +/- 7.9 mmol/L) levels did not show 
      significant differences from the start to the end of the study (P > 0.05). 
      Thirty-eight patients (37%) developed AEs. The most common were abdominal pain 
      (24.5%), diarrhea (8.0%), and nausea (7.8%). AEs were predominantly transient and 
      mild to moderate in nature. CONCLUSIONS: This study has revealed that DFX is a 
      safe, tolerable, and effective drug for reducing IOL in SCD patients, though it 
      is associated with mild and transient adverse events.
FAU - Mohsin, A M
AU  - Mohsin AM
AD  - Center for Hereditary Blood Diseases, Basra Maternity and Children Hospital, 
      Basra, Iraq.
FAU - Hassan, M K
AU  - Hassan MK
AD  - Center for Hereditary Blood Diseases, Basra Maternity and Children Hospital; 
      Department of Pediatrics, College of Medicine, University of Basra, Basra, Iraq.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Niger J Clin Pract
JT  - Nigerian journal of clinical practice
JID - 101150032
RN  - 0 (Benzoates)
RN  - 0 (Iron Chelating Agents)
RN  - 0 (Triazoles)
RN  - 9007-73-2 (Ferritins)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - V8G4MOF2V9 (Deferasirox)
SB  - IM
MH  - Abdominal Pain/etiology
MH  - Alanine Transaminase/blood
MH  - Anemia, Sickle Cell/*therapy
MH  - Benzoates/*therapeutic use
MH  - Blood Transfusion
MH  - Creatinine/blood
MH  - Deferasirox
MH  - Female
MH  - Ferritins/blood
MH  - Humans
MH  - Iraq
MH  - Iron Chelating Agents/adverse effects/*therapeutic use
MH  - Iron Overload/*drug therapy/etiology
MH  - Male
MH  - Treatment Outcome
MH  - Triazoles/*therapeutic use
OTO - NOTNLM
OT  - Basra
OT  - deferasirox
OT  - sickle cell disease
COIS- There are no conflicts of interest
EDAT- 2018/06/12 06:00
MHDA- 2018/09/01 06:00
CRDT- 2018/06/12 06:00
PHST- 2018/06/12 06:00 [entrez]
PHST- 2018/06/12 06:00 [pubmed]
PHST- 2018/09/01 06:00 [medline]
AID - NigerJClinPract_2018_21_6_735_234032 [pii]
AID - 10.4103/njcp.njcp_162_17 [doi]
PST - ppublish
SO  - Niger J Clin Pract. 2018 Jun;21(6):735-742. doi: 10.4103/njcp.njcp_162_17.